Allogeneic peripheral blood stem cell transplantation

Reviews in Clinical and Experimental Hematology

Volumn 5, Issue 2, 2001, Pages 67-86

  Bensinger, William I ^a   Storb, Rainer ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; APHERESIS; CELL COMPARTMENTALIZATION; CELL SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; PERIPHERAL BLOOD STEM CELL; RELAPSE; REVIEW; RISK BENEFIT ANALYSIS; STEM CELL; STEM CELL TRANSPLANTATION;

CELL SEPARATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035382483     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2001.00033.x     Document Type: Review

References (127)

1. Evidence for stem cells in the peripheral blood of mice
2. Cells capable of colony formation in the peripheral blood of man
3. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor
4. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimutating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation
5. Factors that influence collection and engraftment of autologous peripheral-blood stem cells
6. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor
7. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilization, and composition of the graft
8. Single dose of filgrastim (rhG-CSF) increases the number of hematopoietic progenitors in the peripheral blood of adult volunteers
9. The effects of daily recombinant human granulocyte colony stimulating factor administration on normal granulocyte donors undergoing leukapheresis
10. Effective stimulation of donors in granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor
11. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation
12. Peripheral blood stem cells for allografting
13. Peripheral blood stem cells for allogeneic transplantation
14. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts
15. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)
16. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
17. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
18. Allogeneic transplants of rhG-CSF-mobilized peripheral blood stem cells (PBSC) from normal donors
19. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation
20. + peripheral blood stem cells in patients with advanced hematologic malignancy
21. Allogeneic blood cell transplants for haematological malignancy: Comparison of engraftment and graft-versus-host disease with bone marrow transplantation
22. Allogeneic blood stem cell transplantation in advanced hematologic cancers
23. Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematologic malignancies
24. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals
25. Peripheral blood progenitor cell transplantation: A replacement for marrow auto- or allografts
26. Blood stem cells compared with bone marrrow as a source of hematopoietic cells for allogeneic transplantation
27. Mobilized blood stem cells: Immunophenotyyping and functional characteristics
28. Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry
29. + cells
30. Immuno-biology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor
31. Study of the release of CD34 cells and colony forming cells in healthy subjects using G-CSF
32. Composition of peripheral blood progenitor cell components collected from healthy donors
33. The biology and clinical uses of blood stem cells
34. Improved immune reconstitution after allo-transplantation of peripheral blood stem cells instead of bone marrow
35. Mobilization of hemopoietic progenitor cells into peripheral blood is associated with VCAM-1 proteolytic cleavage in the bone marrow
36. In vivo effects of Flt3/Flk2 ligand on mobilization of hemopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor
37. + cells in granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells induce secretion of interleukin-6 and G-CSF by marrow stroma
38. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease
39. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft
40. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft versus host disease
41. + cells derived from granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells
42. +) in the blood of normal donors
43. Granulocyte colony-stimulating factor down-regulates allogeneic immune responses by posttranscriptional inhibition of tumor necrosis factor-α production
44. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy
45. Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: Increased destruction of circulating platelets
46. Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation
47. + cells in normal donors treated with filgrastim
48. + cells in healthy people
49. Alkaline phosphatase and lactate dehydrogenase changes during leucocytosis, induced by G-CSF in testicular cancer
50. Analysis of rhG-CSF-effects on platelets by in vitro bleeding test and transcranial Doppler ultrasound examination
51. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors
52. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor
53. Three to six year follow-up of normal donors who received recombinant human granulocyte colony stimulating factor
54. Allogeneic blood stem cell transplantation: Considerations for donors
55. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): Occurrence in an allogeneic donor of peripheral blood stem cells
56. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor
57. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor
58. Unusual adverse events following peripheral blood stem cell (PBSC) mobilisation using granulocyte colony stimulating factor (GCSF) in healthy donors
59. A cutaneous eruption from G-CSF in a healthy donor
60. Acute gouty arthritis following recombinant human granulocyte colony-stimulating factor therapy in an allogeneic blood stem cell donor
61. Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor
62. Myelodysplasia and acute myeloid leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration
63. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma
64. Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: An open label randomized split dose escalating study
65. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures
66. Mobilization and collection of PBSC in healthy donors: A retrospective analysis of the Italian bone marrow transplantation group (GITMO)
67. Safety of AlloPBPCT donors: Biometrical considerations on monitoring long term risks
68. Bone marrow donors
69. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies
70. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
71. Collection of progenitor cells for allogeneic transplantation from peripheral blood of normal donors
72. + Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease
73. Treatment of normal individuals with granulocyte-colony-stimulating factor: Donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells
74. Administration of recombinant human granulocyte colony-stimulating factor to normal donors: Results of the Spanish National Donor Registry
75. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: The M.D. Anderson Cancer Center experience
76. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors
77. Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: Analysis of serial marrow samples from normal donors
78. Collection of two peripheral blood stem cell concentrates from healthy donors
79. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors
80. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation
81. Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases
82. + peripheral blood progenitor cells in normal donors
83. + cells in association with modulation of CD44 and CD31 expression during continuous intravenous administration of G-CSF in normal donors
84. Peripheral blood progenitor cell mobilization in healthy donors receiving recombinant human granulocyte colony-stimulating factor
85. Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors
86. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: Efficacy and toxicity of a high-dose rhG-CSF regimen
87. Granulocyte colony-stimulating factor administration to healthy volunteers: Analysis of the immediate activating effects on circulating neutrophils
88. Allogeneic peripheral blood progenitor cell transplantation: Analysis of short-term engraftment and acute GVHD incidence in 33 cases
89. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers
90. A randomized dose finding study of filgrastim for mobilization of peripheral blood progenitor cells (PBPCs)
91. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers
92. Collection of peripheral blood stem cells from normal donors 60 years of age or older
93. + progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation
94. A time course study for optimal harvest of peripheral blood progenitor cells by granulocyte colony-stimulating factor in healthy volunteers
95. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF; potential role in allogeneic marrow transplantation
96. + selection systems or CAMPATH-1
97. Cell processing protocol for allogeneic peripheral blood stem cells mobilized by granulocyte colony-stimulating factor
98. Successful engraftment of T-cell-depleted halpoidentical 'Three-Loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum
99. + blood cells
100. Reduction in graft-versus-host-disease (GVHD) after transplantation of CD34 selected, allogeneic peripheral blood stem cells (PBSC) in older patients with advanced hematologic malignancies
101. + cells from peripheral blood: Experience of 62 cases using immunoadsorption or immunomagnetic technique
102. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma
103. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia
104. T-cell depletion for prevention of graft-versus-host disease
105. Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anemia
106. Soybean lectin agglutination and E-rosette depletion for removal of T-cells from HLA-identical and non-identical marrow grafts administered for the treatment of leukemia
107. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
108. Blood and marrow transplantation activity in Europe 1997
109. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation
110. Comparative serial quantitative measurements of chimaerism following unmanipulated allogeneic transplantation of peripheral blood stem cells and bone marrow
111. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors
112. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
113. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
114. Allogeneic peripheral blood stem cell transplantation for haematological malignancies - An analysis of kinetics of engraftment and GVHD risk
115. Long-term follow-up after allogeneic granulocyte colony-stimulating factor-primed bone marrow transplantation
116. Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation
117. Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: A study of 29 patients
118. Marrow transplantation for leukemia and aplastic anemia: Two controlled trials of a combination of methotrexate and cyclosporine versus cyclosporine alone or methotrexate alone for prophylaxis of acute graft-versus-host disease
119. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate
120. A Canadian randomized study comparing peripheral blood (PB) and bone marrow (BM) in patients undergoing matched sibling transplants for myeloid malignancies
121. A randomised study from the European Group for Blood and Marrow Transplantation comparing allogeneic transplantation of filgrastim-mobilised peripheral blood progenitor cells with bone marrow transplantation in 350 patients (pts) with leukemia
122. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation
123. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Société Française de Greffe de Moelle
124. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow
125. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies
126. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation
127. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial